NYSE · AGL
Agilon Health, Inc.
$85.94-$5.06 (-5.56%)
Agilon Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.4% below the high.
Loading market information…
NASDAQ · SLP · USD
Stock price, dividends, earnings
Quote as of Oct 6, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Simulations Plus, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Simulations Plus, Inc.’s forward annual dividend is $0.24 per share, paid quarterly. The forward yield is 1.3% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Simulations Plus, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:40 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | Jan 7, 2025 | $0.17-5.56% vs estimate | $18.92M+0.63% vs estimate |
|---|
| Q4 2024 | Oct 23, 2024 | $0.06-9.09% vs estimate | $18.66M-5.45% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $18.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$85.94-$5.06 (-5.56%)
Agilon Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.4% below the high.
$23.47+$0.14 (+0.6%)
Alto Neuroscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$7.97+$0.10 (+1.27%)
SOPHiA GENETICS S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
$23.49+$0.02 (+0.09%)
NRC Health’s quoted price sits in the upper half of its reported 52-week range, 3.73% below the high.
$2.37$0.00 (0.0%)
AC Immune S.A.’s quoted price sits in the lower half of its reported 52-week range, 39.23% below the high.
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
$9.37+$0.07 (+0.75%)
OptimizeRx Corp.’s quoted price sits in the lower half of its reported 52-week range, 55.57% below the high.
$6.88-$0.25 (-3.51%)
Nakamoto Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.45% below the high.
